1. Home
  2. JRVR vs NKTR Comparison

JRVR vs NKTR Comparison

Compare JRVR & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JRVR
  • NKTR
  • Stock Information
  • Founded
  • JRVR 2002
  • NKTR 1990
  • Country
  • JRVR Bermuda
  • NKTR United States
  • Employees
  • JRVR N/A
  • NKTR N/A
  • Industry
  • JRVR Property-Casualty Insurers
  • NKTR Biotechnology: Pharmaceutical Preparations
  • Sector
  • JRVR Finance
  • NKTR Health Care
  • Exchange
  • JRVR Nasdaq
  • NKTR Nasdaq
  • Market Cap
  • JRVR 241.0M
  • NKTR 238.7M
  • IPO Year
  • JRVR 2005
  • NKTR 1994
  • Fundamental
  • Price
  • JRVR $6.59
  • NKTR $1.32
  • Analyst Decision
  • JRVR Buy
  • NKTR Buy
  • Analyst Count
  • JRVR 6
  • NKTR 4
  • Target Price
  • JRVR $11.17
  • NKTR $2.50
  • AVG Volume (30 Days)
  • JRVR 234.0K
  • NKTR 988.9K
  • Earning Date
  • JRVR 11-05-2024
  • NKTR 11-05-2024
  • Dividend Yield
  • JRVR 3.04%
  • NKTR N/A
  • EPS Growth
  • JRVR N/A
  • NKTR N/A
  • EPS
  • JRVR N/A
  • NKTR N/A
  • Revenue
  • JRVR $815,639,000.00
  • NKTR $93,157,000.00
  • Revenue This Year
  • JRVR N/A
  • NKTR N/A
  • Revenue Next Year
  • JRVR $8.37
  • NKTR N/A
  • P/E Ratio
  • JRVR $3.49
  • NKTR N/A
  • Revenue Growth
  • JRVR 23.89
  • NKTR 6.17
  • 52 Week Low
  • JRVR $6.12
  • NKTR $0.41
  • 52 Week High
  • JRVR $15.47
  • NKTR $1.93
  • Technical
  • Relative Strength Index (RSI)
  • JRVR 49.30
  • NKTR 56.07
  • Support Level
  • JRVR $6.12
  • NKTR $1.11
  • Resistance Level
  • JRVR $6.49
  • NKTR $1.39
  • Average True Range (ATR)
  • JRVR 0.22
  • NKTR 0.09
  • MACD
  • JRVR 0.04
  • NKTR 0.01
  • Stochastic Oscillator
  • JRVR 69.12
  • NKTR 75.00

About JRVR James River Group Holdings Ltd.

James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure. and the Corporate and other segment consists of the management and treasury activities of holding companies, equity compensation for the group.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Share on Social Networks: